Mutations in these genes have previously been linked to distinct glioma subtypes (Ceccarelli et al., 2016; Kannan et al., 2012; Suzuki et al., 2015), and we verified that mutations in IDH1, TP53, and ATRX were most frequently observed in low-grade gliomas, while mutations in PTEN and EGFR were most frequently observed in high-grade glioblastomas (Figure 1—figure supplement 7B). The gene discussed is ATRX; the disease is central nervous system cancer.